Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 11/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3726461 | 0.84 | SMN1; SMN2 (0.41) | CYP11B1CYP11B2CYP3A4CHRNB2CHRNA4 | |
| SCHEMBL13744015 | 0.81 | HRH3 (0.59) | CYP11B1CYP11B2TLR7CHRNB2CHRNA4 | |
| SCHEMBL7845108 | 0.78 | HRH3 (0.50) | CHRNB2CHRNA4HRH3 | |
| SCHEMBL13778367 | 0.77 | CYP2A6 (0.43) | CYP11B1CYP11B2CYP3A4TLR7CHRNB2 | |
| SCHEMBL3422235 | 0.77 | CYP2A6 (0.59) | CYP11B1CYP11B2CYP3A4CYP2A6 | |
| SCHEMBL3792923 | 0.75 | DGAT1 (0.42) | CYP11B1CYP11B2CYP3A4CHRNB2CHRNA4 | |
| SCHEMBL4167777 | 0.75 | CHRNB2 (0.39) | CYP11B1CYP11B2CYP3A4CHRNB2CHRNA4 | |
| SCHEMBL13778325 | 0.74 | HTR7 (0.46) | TLR7CHRNB2CHRNA4CYP2A6 | |
| SCHEMBL10174182 | 0.73 | CHRNB2 (0.48) | CYP11B1CYP11B2CYP3A4TLR7CHRNB2 | |
| SCHEMBL16826311 | 0.72 | CYP11B2 (0.44) | CYP11B1CYP11B2CYP3A4WNT3ACYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | CYP11B1 1713/4885CYP11B2 1994/4885CYP3A4 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.